Get the Stockscreener App
1.14
0.88%
0.01
After Hours:
1.19
0.05
+4.39%
Spero Therapeutics Inc Stock (SPRO) Latest News
Carbapenem Market Size, Trends, Growth, Opportunities - openPR
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates - MSN
TD Cowen Reaffirms “Hold” Rating for Spero Therapeutics (NASDAQ:SPRO) - Defense World
Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Spero Therapeutics' (SPRO) "Hold" Rating Reiterated at TD Cowen - MarketBeat
Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Spero Therapeutics (NASDAQ:SPRO) Given "Overweight" Rating at Cantor Fitzgerald - MarketBeat
Spero Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada
Spero Therapeutics Inc. (SPRO) Quarterly 10-Q Report - Quartzy
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics Reports Wider Q3 Loss, Revenue Falls 47% Amid Restructuring | SPRO Stock News - StockTitan
Spero Therapeutics: Strategic Shift and Earnings Update - TipRanks
What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnin - GuruFocus.com
What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnings - Yahoo Finance
Spero Therapeutics (SPRO) Scheduled to Post Earnings on Thursday - Defense World
Spero Therapeutics (SPRO) to Release Earnings on Thursday - MarketBeat
Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024 - The Manila Times
Spero Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire
HC Wainwright Expects Higher Earnings for Spero Therapeutics - MarketBeat
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights
Spero shares hold Buy rating with target lowered on SPR720 Phase 2a results - Investing.com UK
HC Wainwright Cuts Spero Therapeutics (NASDAQ:SPRO) Price Target to $5.00 - MarketBeat
There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding - Simply Wall St
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Cambridge biotech pulls plug on lung disease drug, cuts 39% of workforce - The Business Journals
Spero Therapeutics to lay off 39% of employees - PharmaLive
Spero Therapeutics stock hits 52-week low at $1.03 By Investing.com - Investing.com South Africa
Spero Therapeutics to Lay Off 39% of Employees - BioSpace
Spero Therapeutics stock hits 52-week low at $1.03 - Investing.com
Spero’s stock slides after antibiotic flops in Phase II trial - Yahoo Finance
Spero Therapeutics reports setback in SPR720 study By Investing.com - Investing.com South Africa
Biopharma Co. Escapes Investor Suit Over Drug Approval Lies - Law360
Spero Therapeutics Stock Falls 21%, Cuts Jobs, Suspends Pulmonary Treatment Development Program - MarketWatch
Spero to cut 39% of workforce on failed study, stock plunges 20% (NASDAQ:SPRO) - Seeking Alpha
Spero Therapeutics reports setback in SPR720 study - Investing.com India
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics Dodges Investor Suit Over FDA Approval (1) - Bloomberg Law
Spero Therapeutics Restructures Focus on Key R&D Projects - TipRanks
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 - The Manila Times
Spero Therapeutics Announces Presentation of SPR719 (Active - GlobeNewswire
Spero Therapeutics reports promising in vitro NTM treatment data - Investing.com
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Market Insight: Spero Therapeutics Inc (SPRO)’s Notable Drop, Closing at 1.24 - The Dwinnex
An Analysis of Spero Therapeutics Inc (SPRO)’s Potential Price Growth - Knox Daily
Spero Therapeutics' (SPRO) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Spero Therapeutics reports promising Phase 1 trial results for NTM-PD drug - Investing.com
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy - ForexTV.com
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):